RU58841 blocks the androgen receptor, the protein that dihydrotestosterone (DHT) binds in hair follicle cells. Finasteride and dutasteride act earlier in the pathway, by lowering the amount of DHT the body makes. RU58841 is sold online as a research chemical.
The short answer: RU58841 is a topical androgen receptor antagonist from the 1990s, and no regulator we could find has approved it. Its two registered human trials finished in 2002 and 2003, and neither has ever posted a result, so there is no published human efficacy or safety data. One published human study exists: in 2026 an anti-doping laboratory gave six men a single topical dose and found the drug in their blood within hours. Everything else comes from cultured cells, rats, hamsters, macaques and human scalp grafts carried on mice.
Our RU58841 treatment science page grades each claim by evidence tier, and the record has changed since it was last reviewed. Everything below is current as of 15 November 2026.
What is RU58841?
RU58841 is a nonsteroidal androgen receptor antagonist: it sits on the receptor and stops testosterone and DHT switching on androgen-driven genes. It is also coded PSK-3841 and HMR-3841, and both codes appear on its trial records.
Roussel Uclaf's own team described it in 1994 as a candidate for the topical treatment of acne, androgenetic alopecia and hirsutism. The design was for a drug that acts where it is applied and breaks down once it reaches the bloodstream (Battmann et al. 1994).
The binding data is specific. RU58841 bound the human androgen receptor with an association constant of 1.8 x 10^9 per mole, against 1.2 x 10^9 per mole for testosterone itself. Roussel Uclaf put its affinity "about 30 times higher than that of other non-steroidal antiandrogens such as Anandron or flutamide" (Battmann et al. 1994).
An independent group later measured function instead of binding. In prostate PC3 cells carrying the human androgen receptor and an androgen-responsive reporter gene, RU58841 had an IC50 of 100 nM, similar to hydroxyflutamide (Pan et al. 1998).
The "soft drug" idea behind RU58841 was characterised in rats. After intravenous dosing at 10 mg/kg the parent compound cleared with an elimination half-life on the order of an hour. Only about 1 percent of it converted to RU56279, the long-lived metabolite that carries systemic antiandrogen activity, while a sister compound in the same chemical series converted at 77 percent and was the systemically active one (Cousty-Berlin et al. 1994).
That contrast, with the hamster data below, underlies the claim that RU58841 stays local. Both were measured in rodents.
What does the animal evidence for RU58841 show?
It is dose-dependent, and almost all of it is about sebaceous glands.
The main model was the hamster flank organ, an androgen-sensitive sebaceous structure used to screen topical antiandrogens. Applied topically to intact hamsters for three weeks, RU58841 shrank flank organ area by 27.1 percent at the lowest dose tested and by 52.4 percent at a dose a hundred times higher. Untreated control organs grew by 11.8 percent (Battmann et al. 1994).
The contralateral untreated organ and the deep androgen-dependent organs showed no significant change at any topical dose. The same investigators calculated that it took 100 to 300 times more drug given subcutaneously to produce the first systemic effects.
The macaque hair data comes from four animals. Investigators applied an RU58841 solution to the frontal bald scalp of four adult stumptailed macaques, a species that balds in a pattern resembling human androgenetic alopecia.
After five months all four showed what the authors called "a marked progressive pattern of folliculograms" on 4 mm punch biopsies. The anagen follicle population was greatly increased and the telogen population reduced, while vehicle-treated scalp showed no regrowth. Body weight, blood chemistry and serum testosterone, DHT and luteinising hormone showed no detectable abnormalities (Pan et al. 1998).
The result was reported qualitatively: the paper contains no hair count, hair weight or caliber figure. Any specific macaque number circulating online has no source.
The closest thing to human evidence is a 1997 graft study. Belgian investigators grafted balding scalp from three men onto female nude mice, and conditioned every mouse with topical testosterone propionate on the ungrafted flank to suppress hair production. Twenty productive grafts, ten per arm, received RU58841 in ethanol or ethanol alone for six months.
Eight of the 29 active follicles in the treated group (28 percent) started a second hair cycle, against two of 28 (7 percent) on vehicle. The linear hair growth rate was significantly greater in the treated grafts (P = 0.0387). The same paper reports no significant treatment effect on the number of hairs, and that "RU58841 had no influence on hair diameter" (De Brouwer et al. 1997).
The second-cycle difference carries no reported test in the paper. By our own calculation it gives a two-sided Fisher exact P of about 0.08.
Is there a human study of RU58841?
Yes, one, published in October 2026. It measured blood and urine, not hair.
Researchers at the Center for Preventive Doping Research at the German Sport University Cologne wanted to know how humans metabolise RU58841, and whether a topical dose shows up systemically. Six healthy male volunteers each received a single application of a commercially sold RU58841 scalp serum. Fingerprick dried blood spots and urine were collected for seven to ten days (Okutan et al. 2026).
The laboratory measured the serum's concentration before using it. It held about 60 percent of the labelled value, with no other drugs detected (Okutan et al. 2026). That is one bottle from one supplier, and the only independent analysis of commercial RU58841 we found in the published literature.
In the dried blood spots the parent compound appeared quickly, reaching maximum levels within the first 12 hours. The highest single concentration recorded was about 5 micrograms per mL. That peak exceeded the method's validated range, so the authors applied a second calibration curve directly to the measured peak areas, a caveat they state in the paper.
Levels fell to near baseline by 36 hours, and after 120 hours only one participant still returned low concentrations below the limit of identification. The mean curve across all six men in the paper's Figure 4 peaks closer to 1 microgram per mL. So the widely repeated 5 micrograms per mL describes one man at one time point. The authors conclude that the parent compound and its oxidised metabolite in blood indicate "considerable systemic exposure to topically applied RU 58841" (Okutan et al. 2026).
The urinary steroid profile markers used in doping control, including the testosterone to epitestosterone ratio, did not change in any of the six participants. The authors also write that RU58841 is intended for long-term use, and that "repeated daily use may result in cumulative or steady-state endocrine adaptations", which their design could not test.
One caveat is ours rather than the paper's. The blood samples were fingerprick spots, taken hours after volunteers applied a serum to their own scalps. The paper does not discuss whether residue on the hands could contribute to the early measurements.
What happened to the two RU58841 clinical trials?
Both finished, and neither reported. RU58841 has two registered human trials under the code PSK-3841, both sponsored by ProStrakan Pharmaceuticals (France):
- ISRCTN49873657, a double-blind, randomised, vehicle-controlled safety and tolerance study of a topical solution over four weeks in men with androgenetic alopecia, run in France, targeting 60 participants. Completed 20 September 2002.
- ISRCTN71083772, a multi-centre, double-blind, randomised, vehicle-controlled study of two solution strengths over six months in the UK and Belgium, targeting 120 participants, with total and anagen hair numbers as a primary outcome. Completed 4 August 2003.
We pulled both records again on 15 November 2026. Every results field is empty in both: no results summary, no posted outcome measures, no adverse event data, no publication link. Neither record states how many people enrolled, so the figures of 60 and 120 are what the trials were built for.
Kyowa Hakko Kirin, now Kyowa Kirin, acquired ProStrakan Group plc on 21 April 2011 (Kyowa Kirin 2011). We have not confirmed who holds the trial data today.
What are the side effects of RU58841?
Nobody has measured them in a published human study, so there is no adverse event rate to quote.
PubMed indexes 18 papers for RU58841, PSK-3841 and HMR-3841 as of 15 November 2026. The only one with human participants is the six-man exposure study above, and it had no adverse event endpoint.
The harms circulating online, including chest tightness and palpitations, gynecomastia, reduced libido and mood changes, come from self-described forum accounts that we could not verify. The earliest source we found for the pulmonary fibrosis claim is a 2017 forum post citing the warning label of a different antiandrogen, nilutamide.
The absence of published harms is not evidence of safety. The 2026 Cologne data showed that a single topical dose produced measurable systemic drug levels in six men. That is the route by which an androgen receptor antagonist could act beyond the scalp. The same study found no change in the steroid profile markers it measured after one dose, and it did not test repeated daily use.
Product quality is a safety concern that needs no trial data. RU58841 is not approved by any regulator we could find, and it is not a compounded prescription medicine. Vendors market it as a research chemical, without pharmaceutical quality control or medical oversight.
A buyer has no routine way to verify a vendor's certificate of analysis. The one bottle independently tested in the published literature held about 60 percent of its labelled concentration, and we found no broader analytical audit of market material.
RU58841 vs finasteride: how do the mechanisms differ?
Finasteride and dutasteride cut how much DHT the body produces. RU58841 leaves DHT production alone and blocks the receptor DHT acts on.
Finasteride inhibits type 2 5-alpha reductase, the enzyme that converts testosterone to DHT, and dutasteride inhibits both type 1 and type 2 (Gubelin Harcha et al. 2014). RU58841 works one step further down the same pathway, competing with DHT for the androgen receptor inside skin cells. In principle that also blocks testosterone acting at the receptor without conversion to DHT, and no human hair study has tested whether that matters.
The evidence behind the two approaches is not comparable. In a randomised, placebo-controlled and active-controlled trial of 917 men over 24 weeks, vertex hair count rose by 18.1 hairs on dutasteride 0.5 mg and by 12.1 hairs on finasteride 1 mg, against a loss of 0.3 hairs on placebo (Gubelin Harcha et al. 2014; results posted under NCT01231607). Those are least squares mean changes within a 1.13 cm circle, almost exactly one square centimetre.
Oral finasteride 1 mg is FDA approved for male pattern hair loss, and dutasteride is used off-label for hair loss in the US. As of 15 November 2026 we found no published hair count from a person using RU58841.
Bicalutamide is an oral androgen receptor antagonist, so it reaches the follicle through the bloodstream and has no delivery problem to solve. In a randomised, double-blind trial of 74 women with female pattern hair loss, 32 completers per group, bicalutamide 25 mg daily was added to minoxidil 1 mg daily. Hair count rose by 18.1 hairs/cm2 against 21.5 hairs/cm2 for minoxidil alone, with P = 0.86 (Libório et al. 2025).
That trial was in women, at a single centre, over 24 weeks, in combination with minoxidil, and it tested a different molecule. It does not predict what RU58841 would do, and it did not compare receptor blockade with DHT lowering.
How does RU58841 compare to clascoterone and pyrilutamide?
All three block the androgen receptor in the skin. The difference is that clascoterone and pyrilutamide have reported Phase 3 scalp results in company announcements, and RU58841's two trials reported nothing.
Clascoterone 1% cream is FDA approved for acne under the brand name Winlevi, where the label describes it as an androgen receptor inhibitor (FDA 2025). Its 5 percent scalp formulation has been taken through late-stage development for androgenetic alopecia under the name Breezula. Kintor Pharmaceutical has announced that a Phase 3 trial of its 1.0 percent pyrilutamide tincture reached its primary endpoint in androgenetic alopecia (Kintor 2026). According to their developers, all three were designed for local action with rapid breakdown, and neither of the two newer compounds has a peer-reviewed paper for its scalp results yet.
Our 2026 treatment tier list places RU58841 in B tier, alongside microneedling, bicalutamide, darolutamide and dimethylcurcumin. A tier holds dutasteride, finasteride, minoxidil, diazoxide and 17-beta-estradiol. The list weighs mechanism together with human evidence, which puts RU58841 above the company-reported late-stage results for clascoterone in C tier and pyrilutamide in D tier.
That placement rests on the animal and graft data for an androgen receptor blocker. RU58841 ranks below finasteride, dutasteride and minoxidil because those drugs have published human hair counts and RU58841 has none. The full list is in our ranking of every hair loss treatment.
What we still do not know about RU58841
The largest gap is efficacy. No published human trial has measured whether RU58841 grows hair, so every efficacy claim rests on four macaques, a sebaceous gland assay in hamsters and twenty scalp grafts on mice. The two trials designed to answer the question finished more than twenty years ago and never reported.
The 2026 study adds a second gap. A single topical dose produced measurable blood levels in all six men, which argues against the rodent-derived assumption that RU58841 stays where it is applied. Nobody has measured what daily use over months does to systemic exposure or endocrine function.
The third gap is the product itself. Only one commercial bottle has ever been independently assayed in the published literature.
All three are answerable. A vehicle-controlled hair count study over six months, of the kind ISRCTN71083772 was designed to be, would measure efficacy at that duration. Publishing the 2003 dataset would add human data at no experimental cost. Until then, the human record for RU58841 stays where it has been since 2003: no published human hair data.
Frequently asked questions
What are the known side effects of RU58841?
There is no published human safety data on RU58841, which is different from saying it has no side effects. No published human study has measured them. The 2026 Cologne study measured blood exposure and urinary steroid markers, with no adverse event endpoint. The harms described online, including chest tightness and gynecomastia, are unverified forum accounts.
How much RU58841 reached the blood in the 2026 study?
In six healthy men given a single topical dose, the drug appeared in dried blood spots within hours, peaked in the first 12 hours and fell to near baseline by 36 hours. The highest single reading was about 5 micrograms per mL in one man, and the mean curve peaked nearer 1 microgram per mL (Okutan et al. 2026).
Is the RU58841 sold online the real thing?
Only one commercial bottle has been independently tested in the published literature. A Cologne anti-doping laboratory measured a scalp serum at about 60 percent of its labelled concentration, and found no other drugs in it. That is one bottle from one vendor, so it says nothing about the rest of the market, which has no published analytical audit.
Why did RU58841 never reach the market?
No public source gives a reason. Two registered trials completed in 2002 and 2003, the sponsor ProStrakan was later acquired by Kyowa Hakko Kirin, and no results were ever posted. No press release, registry entry or publication documents a safety or efficacy failure, so the empty records leave the outcome unknown in both directions.
Is RU58841 better than finasteride?
No head-to-head trial exists, and the evidence bases are not comparable. Finasteride 1 mg is FDA approved for male pattern hair loss and has registry-posted hair counts from trials with hundreds of men. As of 15 November 2026 we found no published hair count from a person using RU58841 at any dose.
Is RU58841 a DHT blocker like finasteride?
No. Finasteride and dutasteride are 5-alpha reductase inhibitors, so they lower how much DHT the body makes. RU58841 leaves DHT levels alone and competes with DHT at the androgen receptor inside skin cells, one step further down the same pathway. Clascoterone and pyrilutamide work at that same receptor step.
References
- Battmann T, Bonfils A, Branche C, et al. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol. 1994;48(1):55-60. DOI: 10.1016/0960-0760(94)90250-xCited in What is RU58841? (2) · What does the animal evidence for RU58841 show?
- Cousty-Berlin D, Bergaud B, Bruyant MC, et al. Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. J Steroid Biochem Mol Biol. 1994;51(1-2):47-55. DOI: 10.1016/0960-0760(94)90114-7Cited in What is RU58841?
- Pan HJ, Wilding G, Uno H, et al. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine. 1998;9(1):39-43. DOI: 10.1385/ENDO:9:1:39Cited in What is RU58841? · What does the animal evidence for RU58841 show?
- De Brouwer B, Tetelin C, Leroy T, Bonfils A, Van Neste D. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. Br J Dermatol. 1997;137(5):699-702. DOI: 10.1046/j.1365-2133.1997.19382053.xCited in What does the animal evidence for RU58841 show?
- Okutan A, Krug O, Fusshoeller G, Piper T, Thevis M. Investigation into the metabolism and elimination behavior of RU 58841, and its influence on the steroid profile in humans. Biomed Chromatogr. 2026;40(10):e70602. DOI: 10.1002/bmc.70602Cited in Is there a human study of RU58841? (3)
- ISRCTN registry. ISRCTN49873657: a double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution over four weeks to healthy Caucasian males with androgenetic alopecia (title abridged). Record retrieved 15 November 2026. https://www.isrctn.com/ISRCTN49873657
- ISRCTN registry. ISRCTN71083772: a multi-centre, double-blind, randomised, vehicle-controlled study for a quantitative estimation of hair re-growth in male subjects with androgenetic alopecia treated over 6 month with two ethanolic PSK 3841 solutions (title abridged). Record retrieved 15 November 2026. https://www.isrctn.com/ISRCTN71083772
- Kyowa Kirin (then Kyowa Hakko Kirin). Consolidated financial results for the six months ended 30 June 2011. Tokyo, 2 August 2011. https://www.kyowakirin.com/media_center/news_releases/2011/pdf/e20110802_01.pdfCited in Is there a human study of RU58841?
- Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498.e3. DOI: 10.1016/j.jaad.2013.10.049. Posted results: ClinicalTrials.gov NCT01231607.Cited in RU58841 vs finasteride (2)
- Libório RDS, Motta AVD, Miot HA, Muller Ramos P. Bicalutamide 25 mg combined with minoxidil 1 mg versus minoxidil 1 mg for female pattern hair loss: a randomized double-blind clinical trial. JAAD Int. 2025;19:48-55. DOI: 10.1016/j.jdin.2024.12.002Cited in RU58841 vs finasteride
- FDA, WINLEVI (clascoterone) cream, 1% prescribing information, NDA 213433. Label effective 2 January 2025, retrieved from the openFDA label database, 15 November 2026. https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22clascoterone%22Cited in How does RU58841 compare to clascoterone and pyrilutamide?
- Kintor Pharmaceutical. Phase III KX-826 tincture 1.0% for AGA reached primary endpoint. Press release, retrieved 15 November 2026. https://en.kintor.com.cn/news_details/22.htmlCited in How does RU58841 compare to clascoterone and pyrilutamide?
This article is for educational purposes only and is not medical advice, and it is not a recommendation to use RU58841. RU58841 is not approved by the FDA or any other regulator for any indication, it is not a compounded prescription medicine, and vendors market it as a research chemical; Anagen does not sell it, and this article deliberately gives no dosing, concentration or sourcing information for it. Oral finasteride 1 mg and topical minoxidil are FDA approved for pattern hair loss; dutasteride, oral minoxidil, topical finasteride and spironolactone are used off-label for hair loss in the United States. Compounded medicines, including Anagen's own, are not FDA approved and have not been tested in their own clinical trials. Any treatment decision should be made with a qualified clinician who knows your history.


